ArticleNature2026
Multidimensional profiling of heterogeneity in supratentorial ependymomas.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- spaGFM is a scalable graph foundation model for spatial transcriptomics analyses.Research square · 2026Article
- Article
Corrections and comments
- Erratum issued
- Update of
Authors and funding
39 authors.
Daeun Jeong *Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Sara G Danielli *Department of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3101-3114
Kendra K MaaßHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
David R GhasemiHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3844-9933
Svenja K TetzlaffNeurology Clinic and European Center for Neurooncology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2893-920X
Ekin ReyhanNeurology Clinic and European Center for Neurooncology, University Hospital Heidelberg, Heidelberg, Germany.
Li JiangDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Shashank KatiyarDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0009-0004-2265-2883
Julia K SundheimerHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Costanza Lo CascioDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Sina NeyaziDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9861-2325
Carlos Alberto Oliveira de Biagi-JuniorDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0700-3135
Elsa CouvillonDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0009-0009-1682-1579
Sophia CastellaniDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Maria Pazyra-MurphyDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Matthew MullallyDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Marc Philipp DehlerNeurology Clinic and European Center for Neurooncology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0009-0000-7129-1181
Bernhard EnglingerDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Andrezza NascimentoDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Gustavo Alencastro Veiga CruzeiroDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Joana G MarquesDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7152-9655
Rebecca D HaaseDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Cuong M NguyenDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Alicia-Christina BaumgartnerDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Jacob S RozowskyDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Olivia A HackDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
McKenzie L ShawDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
Daniela Lotsch-GojoDepartment of Neurosurgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Katharina BrucknerDepartment of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-6633-4009
Andrey KorshunovHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.
Stefan M PfisterHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5447-5322
Marcel KoolHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6557-5468
Tomasz J NowakowskiDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2345-4964
Johannes GojoDepartment of Neurosurgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-8113-3416
Lissa BairdDepartment of Neurosurgery, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7996-1020
Sanda AlexandrescuDepartment of Pathology, Boston Children's Hospital, Boston, MA, USA.
Kristian W PajtlerHopp Childrens Cancer Center (KiTZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3562-6121
Varun VenkataramaniNeurology Clinic and European Center for Neurooncology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2927-0886
Mariella G FilbinDepartment of Pediatric Oncology, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA. Mariella.filbin@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-2613-8126
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tracy T Batchelor · 2013 to 2026
$33.5MShared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI Benjamin Harris Kann · 2023 to 2026
$8.1MHow the 3D Architecture of the Brain Shapes Cancer Cell Fate DecisionsDP2NS127705 · NINDS · DANA-FARBER CANCER INST · PI FILBIN, MARIELLA GRUBER · 2021 to 2024
$2.7MNCI NIH HHS P50 CA165962NCI NIH HHS U54 CA274516NINDS NIH HHS DP2 NS127705
Abstract
Supratentorial ependymomas are aggressive childhood brain cancers that retain features of neurodevelopmental cell types
Indexed as
EpendymomaSupratentorial NeoplasmsAnimalsCell DifferentiationCell MovementCell ProliferationFemaleHumansMaleMiceNeuroepithelial CellsNeuronsSingle-Cell AnalysisTranscriptomeTumor Microenvironment
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.